Quarterly ResultAug 3, 2026, 07:03 AM
Krystal Biotech Q2 VYJUVEK Revenue $119.2M, Net Income $54.8M
AI Summary
Krystal Biotech reported strong financial results for Q2 2026, with global VYJUVEK net product revenue reaching $119.2 million, a 24% increase year-over-year, and net income of $54.8 million. The company maintains a robust balance sheet with $1.1 billion in cash and investments. Krystal Biotech is on track for VYJUVEK launches in Spain and Italy later this year and anticipates multiple clinical data readouts in the second half of 2026 across its pipeline.
Key Highlights
- Q2 2026 VYJUVEK global net product revenue: $119.2 million, up 24% YoY.
- Total VYJUVEK revenue since launch: $965.9 million.
- Q2 2026 net income: $54.8 million, or $1.79 diluted EPS.
- Cash and investments as of June 30, 2026: $1.1 billion.
- FY 2026 Non-GAAP R&D and SG&A expense guidance: $175.0 - $195.0 million.
- VYJUVEK commercial launches expected in Spain and Italy by year-end.
- Top-line data readout for KB803 (IOLITE study) expected in Q4 2026.
Price Impact
More from KRYS